期刊文献+

联合检测甲胎球蛋白、糖抗原125、糖抗原19-9在鉴别肝脏转移瘤中的意义

The differential diagnosis value of combination detection of serum alpha-fetoprotein,Carbohydrate antigens 125 and 19-9 in liver metastases
下载PDF
导出
摘要 目的探讨联合检测甲胎球蛋白(AFP)、糖抗原125(CA125)、糖抗原19-9(CA19-9)在肝细胞癌(HCC)与肝脏转移瘤鉴别诊断中的价值。方法检测93例患者的血清AFP,CA125和CA19-9浓度,其中HCC组45例,肝脏转移瘤组38例,良性肝病组10例。结果①良性肝病组三种标志物均阴性,HCC组AFP阳性率明显高于肝脏转移瘤组,且联合检测AFP、CA125、CA19-9阳性率高达88.9%,明显高于AFP单项检测(P<0.05);②HCC组血清CA19-9和CA125阳性率分别为57.8%和77.8%,联合检测CA19-9、CA125阳性率明显高于肝脏转移瘤组(P<0.05)。结论 AFP仍是诊断肝细胞癌的主要血清学肿瘤标志物,联合检测AFP、CA125、CA19-9可明显提高HCC的敏感性。 Objective To explore the differential diagnosis value of combination detection of serum alpha-fe-toprotein (AFP),Carbohydrate antigens 125 (CA125)and Carbohydrate antigens 19-9(CA19-9)between hepatocel-lular carcinoma (HCC)and liver metastases.Methods The level of serum AFP,CA125 and CA19-9 were detected in 95 patients,including 45 cases of HCC,38 cases of liver metastases,and 10 cases of benign liver disease.Results ① Three markers in patients with benign liver disease were all negative.The positive rate of serum AFP was in-creased significantly (P <0.05)in patients with HCC compared with liver metastases,and the positive rate of joint detection of AFP,CA125 and CA19-9 was 88.9%,which were significantly (P <0.05)higher than AFP detection,② The positive rate of serum CA19-9 and CA125 were 57.8% and 77.8%,respectively,and the positive rate of de-tection of CA19-9 and CA125 significantly (P <0.05)higher in patients with HCC than those of patients with liver metastases.Conclusion AFP is still one of the most important tumor markers in the diagnosis of HCC.Combined de-tection of serum AFP,CA125 and CA19-9 can significantly improve the sensitivity of HCC.
出处 《中国临床保健杂志》 CAS 2013年第6期599-601,共3页 Chinese Journal of Clinical Healthcare
关键词 肝细胞 甲胎蛋白类 CA-125 抗原 CA-19-9 抗原 诊断 鉴别 Carcinoma,hepatocellular alpha-fetoproteins CA-125 antigen CA-19-9 antigen Diagnosis,differential
  • 相关文献

参考文献12

  • 1Chen DS,Sung JL,Sheu JC. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma[J].Gastroenterology,1984,(06):1404-1409.
  • 2Chen L,Ho DW,Lee NP. Enhanced detection of ear-ly hepatocellular carcinoma by serum SELDI-TOF pro-teomic signature combined with alpha-fetoprotein marker[J].Annals of Surgical Oncology,2010,(09):2518-2525.
  • 3Ferlay J,Shin HR,Bray F. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].International Journal of Cancer,2010,(12):2893-2917.
  • 4张思维,李连弟,鲁凤珠,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,戴旭东.中国1990~1992年原发性肝癌死亡调查分析[J].中华肿瘤杂志,1999,21(4):245-249. 被引量:123
  • 5Hao K,Luk JM,Lee NP. Predicting prognosis in hepatocellular carcinoma after curative surgery with com-mon clinicopathologic parameters[J].BMC Cancer,2009.389.
  • 6Koprowski H,Steplewski Z,Mitchell K. Colorectal carcinoma antigens detected by hybridoma antibodies[J].Somatic Cell and Molecular Genetics,1979,(06):957-971.
  • 7Bast RC Jr,Klug TL,Schaetzl E. Monitoring human ovarian carcinoma with a combination of CA 125,CA 19-9,and carcinoembryonic antigen[J].American Journal of Obstetrics and Gynecology,1984,(05):553-559.
  • 8Lopez JB,Balasegaram M,Thambyrajah V. Serum CA 125 as a marker of hepatocellular carcinoma[J].International Journal of Biological Markers,1996,(03):178-182.
  • 9Elias J,Kew MC. Evaluation of CA 125 as a serum marker of hepatocellular carcinoma[J].International Journal of Cancer,1990,(05):805-807.
  • 10Shiraishi N,Sato K,Inomata M. Multivariate prog-nostic study on large gastric cancer[J].Journal of Surgical Oncology,2007,(01):14-18.doi:10.1002/jso.20631.

二级参考文献37

  • 1李卉,曾蒙苏,周康荣,陈刚,缪熙音,张利军,陆秀良,刘豪,陆怡,殷允娟.胰腺癌侵犯胰周主要血管的CT表现分析[J].中华放射学杂志,2005,39(3):293-297. 被引量:36
  • 2李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:226
  • 3刘凌晓,王建华,王小林,颜志平,刘嵘,陈颐,周大勇.中晚期胰腺癌动脉灌注吉西他滨化疗的疗效分析[J].中国医学计算机成像杂志,2007,13(3):202-207. 被引量:15
  • 4汤钊猷 杨秉辉 等.肝癌研究概况与展望[M].北京:北京医科大学中国协和医科大学联合出版社,1993.4-15.
  • 5李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 6Guo X,Cui Z.Current diagnosis and treatment of pancreatic cancer in China[J].Pancreas,2005,31(1):13-22.
  • 7Thomson BN,Banting SW,Gibbs P.Pancreatic cancer-current management[J].Aust Fam Physician,2006,35(4):212-217.
  • 8National Comprehensive Cancer Network.Clinical practice guidelines in oncology:pancreatic cancer[R/OL].[2009-04-28].http://www.nccn.org.
  • 9Saif MW.New developments in the treatment of pancreatic cancer[J].JOP,2008,9(4):391-397.
  • 10De Jong MC,Farnell MB,Sclabas G,et al.Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy:a dual-center analysis[J].Ann Surg,2010,252(1):142-148.

共引文献159

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部